New guidelines aim to lower costs of rheumatoid arthritis drugs

An international panel has developed recommendations for cost-effective use of expensive biological and targeted drugs for inflammatory rheumatic diseases. The guidance could help hospitals and payers reduce spending on treatments that often cost tens of thousands of dollars annually while maintaining patient outcomes.

Originaltitel: Points to consider for cost-effective use of biological and targeted synthetic DMARDs in inflammatory rheumatic diseases: results from an umbrella review and international Delphi study